Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$47.57 – $76.95
39% from low
Sector
MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES
Exchange
NASDAQ
UNIT
P/S (TTM)
2.4
EV / FCF (TTM)
17.7
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
www.novanta.comNo one on the platform currently holds NOVTU.
No tracked institution reports a position in NOVTU as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-31 | $0.8125 | 2026-08-03 |
| 2026-04-30 | $0.8125 | 2026-05-01 |
| 2026-01-30 | $0.7132 | 2026-02-02 |
No one on the platform has traded NOVTU yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.1% | — | — | — | ||
| Rev. Growth % | ||||||
| Profit Margin % | 5.5% | |||||
| Free Cash Flow Margin % | 4.9% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -0.7% on the P/E track.
At today's price, your expected annual return is +12.9% on the P/E track.
At today's price, your expected annual return is +24.2% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | +15.9% | $3.69 | $2.72–$4.67 | 16.0× | 2 |
| 2027 | $1.3B | +15.9% | $4.37 | $2.88–$5.85 | 13.5× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $0.83 | $0.89 | +7.2% |
| 2026-05-11 | $0.78 | $0.81 | +4.2% |
| 2026-02-23 | $0.88 | $0.91 | +3.4% |
| 2025-11-03 | $0.82 | $0.87 | +6.5% |
| 2025-08-05 | $0.73 | $0.76 | +3.7% |
| 2025-05-06 | $0.67 | $0.74 | +10.0% |
| 2025-02-25 | $0.71 | $0.76 | +6.6% |
| 2024-11-05 | $0.85 | $0.85 | -0.4% |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.